How An End-To-End CDMO Simplifies And Speeds Drug Development & Manufacture

By Northway Biotech

Biotech and biopharma companies face difficult resourcing decisions between cell line development and commercial production. Chief among these decisions is whether to utilize multiple smaller or specialized CDMOs or to trust an end-to-end CDMO with the entirety of the project. Ultimately, this decision is based on a variety of factors, including the molecule, logistical concerns, and costs.

Utilizing a mix of vendors follows traditional wisdom, adhering to the adage it is best not to put all of one’s eggs in a single basket. First, a company that partners with multiple vendors seemingly minimizes risk by spreading liability. Second, the company may require a physical global presence, near major markets in the United States, South America, Europe, and Central America. Sometimes, it can take multiple CDMO partners to meet the company’s regulatory documentation, process development, and production capacity needs.

However, an end-to-end CDMO service provider offers its clients and internal teams efficient access to technical, process, and regulatory experts under one roof. In addition to enabling close control of each development and manufacturing step, this approach also ensures no decision-making occurs without consensus between project teams that predictable risks have been mitigated.